Loading...
XHKG
2005
Market cap1.19bUSD
Jul 18, Last price  
3.16HKD
1D
1.61%
1Q
6.04%
Jan 2017
27.94%
IPO
643.53%
Name

SSY Group Ltd

Chart & Performance

D1W1MN
P/E
8.79
P/S
1.62
EPS
0.36
Div Yield, %
5.70%
Shrs. gr., 5y
-0.58%
Rev. gr., 5y
4.49%
Revenues
5.77b
-10.67%
849,916,765858,323,1461,180,455,3481,591,028,0001,739,628,0001,971,657,0002,155,215,0002,430,684,0002,745,316,0002,091,471,0002,221,921,0002,361,250,0003,076,369,0004,180,787,9994,635,675,0004,260,898,0005,356,763,0006,434,025,0006,463,009,0005,773,251,000
Net income
1.06b
-19.53%
111,962,68993,115,546123,833,773102,106,000216,095,000260,592,000-41,401,000281,003,000411,814,000602,929,000403,416,000489,535,000664,719,000911,774,0001,136,101,000611,971,000785,533,0001,122,837,0001,318,616,0001,061,150,000
CFO
0k
-100.00%
136,783,61925,180,00289,490,122142,685,000228,241,000287,807,000171,498,000242,068,000597,922,000307,607,000562,694,000686,484,000552,438,000969,825,000669,355,000527,644,000747,906,000786,824,000925,747,0000
Dividend
Sep 12, 20240.08 HKD/sh
Earnings
Aug 26, 2025

Profile

SSY Group Limited, an investment holding company, researches, develops, manufactures, and sells various pharmaceutical products to hospitals and distributors in the People's Republic of China and internationally. The company offers intravenous infusion solutions, including non-PVC soft bags, upright soft bags, PP plastic bottles, and glass bottle infusion solutions, as well as ampoule injections. It also provides small volume injections, oral preparations, Chinese medicine preparations, and biological preparations, as well as bulk pharmaceutical products and medical materials. In addition, the company is involved in the research, development, and consulting of pharmaceutical technology; provision of logistics services for pharmaceutical products; and food, beverages, and catering business. It sells its products under Shimen brand name. The company was formerly known as Lijun International Pharmaceutical (Holding) Co., Ltd. and changed its name to SSY Group Limited in May 2015. The company was incorporated in 2004 and is headquartered in Wanchai, Hong Kong. SSY Group Limited is a subsidiary of China Pharmaceutical Co., Ltd.
URL
http://www.ssygroup.com.hk/
IPO date
Dec 20, 2005
Employees
5,300
Domiciled in
HK
Incorporated in
KY

Valuation

Title
HKD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
5,773,251
-10.67%
6,463,009
0.45%
6,434,025
20.11%
Cost of revenue
4,573,593
4,662,776
5,165,906
Unusual Expense (Income)
NOPBT
1,199,658
1,800,233
1,268,119
NOPBT Margin
20.78%
27.85%
19.71%
Operating Taxes
205,995
254,281
209,602
Tax Rate
17.17%
14.12%
16.53%
NOPAT
993,663
1,545,952
1,058,517
Net income
1,061,150
-19.53%
1,318,616
17.44%
1,122,837
42.94%
Dividends
(445,507)
(388,116)
Dividend yield
3.03%
3.02%
Proceeds from repurchase of equity
(32,969)
(89,089)
BB yield
0.22%
0.69%
Debt
Debt current
657,210
1,422,761
1,647,883
Long-term debt
2,986,239
1,957,274
1,563,367
Deferred revenue
203,714
160,390
Other long-term liabilities
264,600
(160,390)
Net debt
1,930,611
1,176,623
954,608
Cash flow
Cash from operating activities
925,747
786,824
CAPEX
(528,469)
(418,123)
Cash from investing activities
(640,194)
(412,773)
Cash from financing activities
(304,571)
(219,302)
FCF
188,342
618,384
1,002,121
Balance
Cash
1,292,701
1,615,208
1,758,360
Long term investments
420,137
588,204
498,282
Excess cash
1,424,175
1,880,262
1,934,941
Stockholders' equity
7,535,650
7,555,020
6,513,169
Invested Capital
10,015,765
8,966,232
7,924,161
ROIC
10.47%
18.31%
13.56%
ROCE
10.49%
16.57%
12.84%
EV
Common stock shares outstanding
2,963,122
2,978,999
2,985,389
Price
3.57
-27.73%
4.94
14.62%
4.31
7.21%
Market cap
10,578,346
-28.12%
14,716,255
14.37%
12,867,027
5.58%
EV
12,824,367
16,229,036
14,153,859
EBITDA
1,199,658
2,205,807
1,639,174
EV/EBITDA
10.69
7.36
8.63
Interest
125,413
90,905
Interest/NOPBT
6.97%
7.17%